JP2012527484A - 哺乳動物疾患の治療におけるエンドキシフェンの方法および組成物 - Google Patents

哺乳動物疾患の治療におけるエンドキシフェンの方法および組成物 Download PDF

Info

Publication number
JP2012527484A
JP2012527484A JP2012512075A JP2012512075A JP2012527484A JP 2012527484 A JP2012527484 A JP 2012527484A JP 2012512075 A JP2012512075 A JP 2012512075A JP 2012512075 A JP2012512075 A JP 2012512075A JP 2012527484 A JP2012527484 A JP 2012527484A
Authority
JP
Japan
Prior art keywords
endoxifen
composition
acid
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012512075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527484A5 (enExample
Inventor
アーマド，アティーク
アリ，ショウカス，エム．
アーマド，モギス，ユー．
シェイク，サイフディン
アーマド，イムラン
Original Assignee
ジャイナ ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャイナ ファーマシューティカルズ，インコーポレーテッド filed Critical ジャイナ ファーマシューティカルズ，インコーポレーテッド
Publication of JP2012527484A publication Critical patent/JP2012527484A/ja
Publication of JP2012527484A5 publication Critical patent/JP2012527484A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012512075A 2009-05-21 2010-05-21 哺乳動物疾患の治療におけるエンドキシフェンの方法および組成物 Pending JP2012527484A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/470,219 2009-05-21
US12/470,219 US20090291134A1 (en) 2006-11-21 2009-05-21 Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PCT/US2010/035852 WO2010135703A2 (en) 2009-05-21 2010-05-21 Endoxifen methods and compositions in the treatment of mammalian diseases

Publications (2)

Publication Number Publication Date
JP2012527484A true JP2012527484A (ja) 2012-11-08
JP2012527484A5 JP2012527484A5 (enExample) 2013-07-11

Family

ID=43126804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012512075A Pending JP2012527484A (ja) 2009-05-21 2010-05-21 哺乳動物疾患の治療におけるエンドキシフェンの方法および組成物

Country Status (6)

Country Link
US (3) US20090291134A1 (enExample)
EP (1) EP2432462A4 (enExample)
JP (1) JP2012527484A (enExample)
CA (1) CA2757838C (enExample)
MX (1) MX2011012409A (enExample)
WO (1) WO2010135703A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101493877B1 (ko) * 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
JP2020533283A (ja) * 2017-09-11 2020-11-19 アトッサ セラピューティクス，インク． エンドキシフェンを製造および使用する方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013251749B2 (en) * 2012-04-24 2019-01-17 International Stem Cell Corporation Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
SG11201407412QA (en) * 2012-06-05 2014-12-30 Int Stem Cell Corp Method of prevention of neurological diseases
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
WO2014141292A2 (en) * 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
JP6895252B2 (ja) 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN110044998B (zh) * 2014-05-12 2021-12-14 奎斯特诊断投资公司 通过质谱法定量他莫昔芬及其代谢物
EP3151837B1 (en) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
CN104892918B (zh) * 2015-05-29 2017-08-25 吕常海 磷脂酰乙醇胺‑羟基聚乙二醇衍生物及制备方法、脂质体造影剂和治疗肿瘤脂质体诊疗药物
EP3448374B1 (en) 2016-04-27 2025-02-12 Signpath Pharma Inc. Prevention of drug-induced atrio-ventricular block
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
PH12022550860A1 (en) * 2019-10-09 2023-06-14 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
US20210322342A1 (en) * 2020-04-10 2021-10-21 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
CA3185993A1 (en) * 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
AU2021252229A1 (en) * 2020-04-10 2022-10-27 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar I disorder
WO2022026796A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
WO2022109602A1 (en) * 2020-11-20 2022-05-27 Academia Sinica Use of crassocephalum rabens extract in the prevention and/or treatment of fatigue and/or depression
AU2024409147A1 (en) * 2023-12-18 2026-06-25 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528489A (ja) * 1998-11-04 2002-09-03 アストラゼネカ アクチボラグ 神経系障害
WO2005105063A1 (en) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
WO2008048194A1 (en) * 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
WO2008070463A2 (en) * 2006-11-21 2008-06-12 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU736301B2 (en) * 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
HUE031951T2 (en) * 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
US9637515B2 (en) 2006-11-06 2017-05-02 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20120164075A1 (en) 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528489A (ja) * 1998-11-04 2002-09-03 アストラゼネカ アクチボラグ 神経系障害
WO2005105063A1 (en) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
WO2008048194A1 (en) * 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
WO2008070463A2 (en) * 2006-11-21 2008-06-12 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014024360; Ｎｅｕｒｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．５２，　Ｎｏ．２, 2007, ｐ．５１５-５２６ *
JPN6014024362; Ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．６７，　Ｎｏ．１, 2006, ｐ．２０-２７ *
JPN6014024364; Ｓｃｈｉｚｏｐｈｒｅｎｉａ　Ｒｅｓｅｒａｃｈ Ｖｏｌ．３９, 1999, ｐ．１５３-１５８ *
JPN7014001796; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｏｎｃｏｌｏｇｙ Ｖｏｌ．２５，　Ｎｏ．３３, 2007, ｐ．５１４７-５１４９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101493877B1 (ko) * 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
US9029334B2 (en) 2013-03-29 2015-05-12 Lifetree Biotech Co., Ltd. Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative
JP2020533283A (ja) * 2017-09-11 2020-11-19 アトッサ セラピューティクス，インク． エンドキシフェンを製造および使用する方法
JP2023126540A (ja) * 2017-09-11 2023-09-07 アトッサ セラピューティクス，インク． エンドキシフェンを製造および使用する方法
JP7766316B2 (ja) 2017-09-11 2025-11-10 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンを製造および使用する方法
JP7901563B2 (ja) 2017-09-11 2026-08-06 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンを製造および使用する方法

Also Published As

Publication number Publication date
US20210177752A1 (en) 2021-06-17
CA2757838C (en) 2013-12-17
EP2432462A4 (en) 2013-11-13
CA2757838A1 (en) 2010-11-25
US20090291134A1 (en) 2009-11-26
EP2432462A2 (en) 2012-03-28
WO2010135703A3 (en) 2011-01-13
MX2011012409A (es) 2012-03-14
WO2010135703A2 (en) 2010-11-25
US11672758B2 (en) 2023-06-13
US20190231687A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US11672758B2 (en) Endoxifen methods and compositions for inhibition of protein kinase C
JP2010510327A (ja) エンドキシフェンの方法および組成物
JP5762390B2 (ja) 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
US20120164075A1 (en) Endoxifen methods and compositions in the treatment of mammalian diseases
JP6197292B2 (ja) 閉経を処置するためのｄｈｅａ組成物
EP1482925B1 (en) 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl]-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
DE60318092T2 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
EP0955042B1 (fr) Composition pharmaceutique à base d'estrogène et de progestérone
JP2010511730A (ja) テストステロンおよびプロゲスターゲンを用いたドライアイのための処置
NO20150741L (no) Fulvestrant-formulering og sprøyte eller glassbeholder inneholdende samme
JP2009536931A (ja) ４，１７β−ジヒドロキシアンドロスト−４−エン−３−オンの新規な使用
KR20170127044A (ko) 에스트로겐-관련 질병의 치료 또는 예방 방법
JP2003510336A (ja) 虚血性損傷においてのエストロゲンのエナンチオマーを用いる細胞保護の方法
WO2015035410A1 (en) Cancer therapy
CN105073118A (zh) 用于经口递送的脂平衡长链睾酮酯
FR2859910A1 (fr) Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate
HK1136198B (en) Endoxifen for use in the treatment of cancer
HK1136198A (en) Endoxifen for use in the treatment of cancer
Powles et al. Endocrine prevention of breast cancer
EP2456423A2 (en) Treatment of hyperproliferative conditions
HK40007321A (en) Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof
HK40107023A (en) Cannabidiolic acid esters for treating prader-willi syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150331